000			02159nam a22003497a 4500
001			20240607164401.0
003			20240607164401.0
005			20240607165345.0
008			240607b |||||||| |||| 00| 0 eng d
040			_cddc
041			_aEnglish
100			_qLukas Scheller
245			_aBCMA CAR-T cells in multiple myeloma-ready for take-off?
260			_aMwanza, Tanzania : _bCatholic University of Health and Allied Sciences [CUHAS-Bugando] : _c2023
300			_aPages 143-157
300			_aIncludes References
490			_vLeukemia & Lymphoma Volume 65, 2024 - Issue 2
520			_aAbstract : Although the approval of new drugs has improved the clinical outcome of multiple myeloma (MM), it was widely regarded as incurable over the past decades. However, recent advancements in groundbreaking immunotherapies, such as chimeric antigen receptor T cells (CAR-T), have yielded remarkable results in heavily pretreated relapse/refractory patients, instilling hope for a potential cure. CAR-T are genetically modified cells armed with a novel receptor to specifically recognize and kill tumor cells. Among the potential targets for MM, the B-cell maturation antigen (BCMA) stands out since it is highly and almost exclusively expressed on plasma cells. Here, we review the currently approved BCMA-directed CAR-T products and ongoing clinical trials in MM. Furthermore, we explore innovative approaches to enhance BCMA-directed CAR-T and overcome potential reasons for treatment failure. Additionally, we explore the side effects associated with these novel therapies and shed light on accessibility of CAR-T therapy around the world.
600			_xBCMA
600			_xmultiple myeloma
600			_xclinical trials
600			_xCAR-T
600			_xchimeric antigen receptor T cell
700			_q Erius Tebuka
700			_qPeter Fabian Rambau
700			_qHermann Einsele
700			_qMichael Hudecek
700			_qSabrina Rebecca Prommersberger
700			_qSophia Danhof
856			_uhttps://doi.org/10.1080/10428194.2023.2276676 _yhttps://doi.org/10.1080/10428194.2023.2276676
942			_2ddc _cVM _n0
999			_c27976 _d27976